Status re Novo Nordisk's holding of its own shares (30 June 2008)
In continuation of the company's announcement dated 31 January 2008
concerning a planned share repurchase programme, and pursuant to
Section 204.25 of the New York Stock Exchange Listed Company Manual,
this is to report that Novo Nordisk A/S (NYSE: NVO) and its
wholly-owned affiliates on 30 June 2008 owned 16,571,430 of its own B
shares of DKK 1, corresponding to a total nominal value of DKK
16,571,430 or 2.61% of the total share capital.
In the second quarter of 2008 a total of 2,810,000 B shares were
repurchased, and 296,660 B shares were disposed of to employees in
connection with employee incentive programs. Furthermore, 12,960,000
B shares were cancelled on 13 June 2008.
Novo Nordisk is a healthcare company and a world leader in diabetes
care. In addition, Novo Nordisk has a leading position within areas
such as haemostasis management, growth hormone therapy and hormone
replacement therapy. Novo Nordisk manufactures and markets
pharmaceutical products and services that make a significant
difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs approximately 26,300
employees in 80 countries, and markets its products in 179 countries.
Novo Nordisk's B shares are listed on the stock exchanges in
Copenhagen and London. Its ADRs are listed on the New York Stock
Exchange under the symbol 'NVO'. For more information, visit
novonordisk.com
For further information please contact:
Media: Investors:
Outside North America: Outside North America:
Elin K Hansen Mads Veggerby Lausten
Tel: (+45) 4442 3450 Tel: (+45) 4443 7919
ekh@novonordisk.com mlau@novonordisk.com
Hans Rommer
Tel: (+45) 4442 4765
hrmm@novonordisik.com
In North America: In North America:
Sean Clements Christian Qvist Frandsen
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.com cqfr@novonordisk.com
Stock Exchange Announcement no 42 / 2008